Eli Lilly Stock Tumbles On Lowered Guidance As Weight-Loss Drug …

Jan 14, 2025 · Eli Lilly on Tuesday lowered guidance for its December quarter amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs.Eli Lilly stock tumbled on the …

CouponFollow Extension

$2
OFF

Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales …

3 weeks from now

The race to develop new weight-loss drugs has been heating up.. LLY Stock Technical Ratings. Earlier this week, Eli Lilly said it would spend $2.5 billion to acquire a cancer drug from …

msn.com

6%
OFF

Eli Lilly Shares Drop As Drugmaker Cuts Revenue Guidance On …

3 weeks from now

Jan 14, 2025 · The drugmaker's shares closed more than 6% lower on Tuesday. Eli Lilly said it now expects full-year 2024 revenue of about $45 billion. That's lower than the $45.4 billion to …

nbcphiladelphia.com

8%
OFF

Lilly Shares On Track For Worst Day Since 2021 After Downbeat …

3 weeks from now

Jan 14 (Reuters) - Eli Lilly's (LLY.N), opens new tab stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, …

reuters.com

$600
OFF

Eli Lilly's Rare Sales Miss For Weight-Loss Drug Sends Shares …

3 weeks from now

Oct 30, 2024 · The drug is sold under the brand name Mounjaro for both diabetes and weight loss outside the U.S. Lilly trimmed the upper end of its full-year sales forecast by $600 million to …

usnews.com

7%
OFF

Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight …

3 weeks from now

Jan 14, 2025 · Shares of Eli Lilly & Co. dropped over 7% on Tuesday morning, reaching levels last seen in late November and marking the stock’s worst day since March 15, 2021. The …

stocktwits.com

20%
OFF

Eli Lilly Stock Hits Profit Zone Amid Weight Loss Drug Enthusiasm ...

3 weeks from now

Sep 20, 2023 · Drug giant Eli Lilly stock reached the 20%-25% profit zone after an August breakaway gap amid Wall Street enthusiasm for weight-loss drugs. ... Eli Lilly Tumbles On …

investors.com

7%
OFF

Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is The Stock ...

3 weeks from now

Jan 23, 2025 · On Jan. 14, Eli Lilly released its guidance for the fourth quarter of 2024, as well as the full year of 2025. And investors weren't thrilled with the numbers, leading to a 7% drop in …

fool.com

$45
OFF

Lilly Provides Update On 2024 Revenue Guidance, Announces 2025 …

3 weeks from now

INDIANAPOLIS, Jan. 14, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, …

lilly.com

3%
OFF

Eli Lilly Dives On 'Big' Miss For Diabetes, Weight-Loss Drugs

3 weeks from now

Oct 30, 2024 · But on today's stock market, Eli Lilly stock plummeted 6.3% to 846.83. Shares undercut their 200-day line and the lower edge of a flat base with a buy point at 972.53, …

investors.com

40%
OFF

Eli Lilly Stock's Correction Brings Opportunity (NYSE:LLY)

3 weeks from now

2 days ago · Intro & Thesis. Occupying over 40% of a fast-growing weight loss drug market, Eli Lilly and Company (NYSE:LLY) stock has been growing at a CAGR of over 30% since 2015 to …

seekingalpha.com

$58
OFF

Eli Lilly's SWOT Analysis: Stock Soars On GLP-1 Success, Faces ... - MSN

3 weeks from now

Eli Lilly's 2025 revenue guidance of $58-$61 billion is ambitious and relies heavily on the continued success of its GLP-1 franchise. Several factors could impede the company's ability …

msn.com

7%
OFF

Lilly's Tirzepatide Achieved Up To 15.7% Weight Loss In Adults With ...

3 weeks from now

Apr 27, 2023 · Participants with obesity or overweight and type 2 diabetes taking tirzepatide lost up to 34.4 lb. (15.6 kg) Lilly plans to complete rolling submission to the FDA in the coming …

lilly.com

FAQs about Eli Lilly Stock Tumbles On Lowered Guidance As Weight-Loss Drug … Coupon?

Is Eli Lilly stock a good buy?

Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity? Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels. ...

Why did Eli Lilly's stock tumble 8% on Tuesday?

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed since the drug's launch in late 2023. ...

Why did Eli Lilly stock fall on lowered Q4 guidance?

Eli Lilly stock fell on lowered Q4 guidance amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs. ...

Why did Eli Lilly stock drop in December?

Eli Lilly on Tuesday lowered guidance for its December quarter amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs. Eli Lilly stock tumbled on the news. For the December quarter, the Indianapolis-based company said it expects revenue of about $13.5 billion, below consensus estimates of $13.93 billion. ...

Why did Eli Lilly stock crash Wednesday?

Eli Lilly (LLY) stock crashed Wednesday after the pharma giant cut its 2024 outlook following a "big" miss for its popular diabetes and weight-loss drugs. The company's drug, tirzepatide, provides the backbone for diabetes treatment Mounjaro and weight-loss drug Zepbound. In the September quarter, Mounjaro sales rocketed 121% to $3.11 billion. ...

Why did Eli Lilly cut its profit guidance?

The drugmaker also slashed its full-year adjusted profit guidance to a range of $13.02 to $13.52 per share. Skyrocketing demand for injectable weight loss and diabetes drugs has forced both Eli Lilly and its main rival, Novo Nordisk, to invest billions to increase manufacturing capacity. ...